# Study Evaluating the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of SAM-315 in Healthy Adults

> **NCT00479440** · PHASE1 · COMPLETED · sponsor: **Wyeth is now a wholly owned subsidiary of Pfizer** · enrollment: 56 (—)

## Conditions studied

- Alzheimer Disease

## Interventions

- **DRUG:** SAM-315

## Key facts

- **NCT ID:** NCT00479440
- **Lead sponsor:** Wyeth is now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-08
- **Primary completion:** —
- **Final completion:** 2007-03
- **Target enrollment:** 56 (—)
- **Last updated:** 2007-12-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00479440

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00479440, "Study Evaluating the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of SAM-315 in Healthy Adults". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00479440. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*